CJC-1295 and Opioids (Oxycodone, Hydrocodone, Tramadol): Interaction Risk, Mechanisms, and Clinical Guidance
At a glance
- Data on CJC-1295 with opioids / None
- CJC-1295 effect / GH up 2- to 10-fold, IGF-I up 1.5- to 3-fold after one dose [3]
- Opioid endocrine data / IGF-I SD score below -2 in 12 of 73 people on intrathecal opioids [2]
- CJC-1295 status / Not FDA-approved; no approved dose [1]
- Opioid boxed warning / Combining an opioid with a benzodiazepine or other CNS depressant can cause coma and death [4]
- What the trials measured / GH, IGF-I and peptide levels, not opioid levels [3][5]
What CJC-1295 does, and how much human data exist
CJC-1295 is a long-acting analogue of growth hormone-releasing hormone (GHRH). It acts on the pituitary to raise the body's own GH and, through GH, IGF-I [3][5]. Two forms are described: CJC-1295, a 29-amino-acid peptide, and CJC-1295 DAC, the same peptide with an extra unit that binds blood albumin and keeps it in circulation much longer [1].
After one subcutaneous injection of the DAC form, the estimated half-life was 5.8 to 8.1 days, mean plasma GH rose 2- to 10-fold for 6 days or more, and mean IGF-I rose 1.5- to 3-fold for 9 to 11 days [3]. In a second study, GH pulses kept their normal frequency and size while between-pulse GH rose about 7.5-fold, mean GH rose 46% and mean IGF-I rose 45% [5].
FDA identified only three published human studies, all of the DAC form and all in healthy volunteers, and none in people with a disease [1]. CJC-1295 is not FDA-approved and has no approved dose. The doses used in research were single injections of about 30 to 250 micrograms/kg, or two or three doses given weekly or every two weeks; these are study doses, not recommendations [1][3].
Is there a pharmacokinetic interaction?
CJC-1295's long duration comes from albumin binding [3]. The published human studies measured GH and IGF-I, and the Teichman study also measured the peptide itself, but none reported opioid levels [3][5]. Whether the peptide changes how oxycodone, hydrocodone or tramadol is handled is unknown.
Do opioids lower the GH and IGF-I response?
In a study of 73 people receiving intrathecal opioids for noncancer pain and 20 people with comparable pain who were not receiving opioids, IGF-I was significantly lower in the opioid group (P = 0.002), and 12 of the 73 had an IGF-I SD score below -2 [2]. Mean duration of opioid treatment was 26.6 months and the mean daily morphine dose was 4.8 mg [2]. Twenty-four-hour urinary free cortisol was below 20 micrograms/day in 14 of 71 opioid-treated patients, and the peak cortisol response to insulin-induced hypoglycemia was below 180 micrograms/L in 9 of 61 [2].
That was intrathecal morphine delivered by pump, not oral oxycodone, hydrocodone or tramadol, so it does not give the size of any effect from tablets. A retrospective cohort of 1,159 men taking a single opioid for at least 90 days found higher odds of androgen deficiency with oxycodone than with hydrocodone (odds ratio 3.15, 95% CI 1.87 to 5.33), and higher odds still with methadone (7.33, 95% CI 3.29 to 16.33) and fentanyl (25.7, 95% CI 2.82 to 234.97) [6]. That study measured testosterone, not GH or IGF-I [6].
No study has tested whether an opioid's endocrine effect reduces what CJC-1295 achieves.
What the opioid labels warn about
In August 2016, FDA required boxed warnings on opioid analgesics, opioid cough products and benzodiazepines - nearly 400 products - describing the serious risks of combining an opioid with a benzodiazepine or other CNS depressant, including alcohol: extreme sleepiness, slowed or difficult breathing, coma and death [4]. This warning concerns those sedatives; CJC-1295 is not named in it.
What CJC-1295 itself has caused in trials
In the Teichman trials of healthy adults, injection-site reactions occurred in about 70% of treated subjects in study 1 and in all treated subjects in study 2. In study 1, headache occurred in 63% versus 14% on placebo, and flushing, warmth and transient low blood pressure in about 30% of treated subjects. Transient diarrhea and transient dizziness with low blood pressure were also reported, and no serious adverse reactions were reported [1][3]. In healthy men given one dose of 60 or 90 micrograms/kg, dose-dependent increases in heart rate were reported [1]. Most events were more common at 125 or 250 micrograms/kg than at 30 or 60 micrograms/kg [1][3].
FDA's stated concern about GH-raising peptides is that elevated GH and IGF-I carry the risks listed on approved growth hormone labels, including glucose intolerance and diabetes, fluid retention and tumor growth concerns, and that the human studies were short, small and mostly single-dose, so long-term safety is unknown [1].
Frequently asked questions
Can you take CJC-1295 with oxycodone or hydrocodone?
Will tramadol reduce how well CJC-1295 works?
Is CJC-1295 safe to take with opioid painkillers?
Does CJC-1295 make opioid sedation or breathing problems worse?
What blood tests would show whether CJC-1295 is working?
Does CJC-1295 interact with opioid metabolism in the liver?
References
Show all 8 referencesHide references
- U.S. Food and Drug Administration.
- Abs R, Verhelst J, Maeyaert J, Van Buyten JP, Opsomer F, Adriaensen H, et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab. 2000;85(6):2215-22.
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.
- New Safety Measures Announced for Opioid Analgesics, Prescription Opioid Cough Products, and Benzodiazepines | FDA.
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-7.
- Rubinstein AL, Carpenter DM. Association Between Commonly Prescribed Opioids and Androgen Deficiency in Men: A Retrospective Cohort Analysis. Pain Med. 2017;18(4):637-644.
- Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S. Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ. 2017;356:j760.
- Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ. 2015;350:h2698.